Biotech · Public company · Emeryville, CA, US
Estrella Immunopharma, Inc.
Ticker ESLA · SEC CIK 0001844417
Track this companyFree. Adds Estrella Immunopharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline1
- EB103Phase 2 · B-Cell Non-Hodgkin's Lymphoma (NHL)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)PHASE1_PHASE2 · RECRUITING · started Jun 1, 2024ClinicalTrials.gov NCT06343311 · fetched Nov 12, 2026
SEC filings12
- 8-K · CURRENT REPORTSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Aug 21, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
- 10-K/A · AMENDMENT NO. 1 TO FORM 10-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 10-K · ANNUAL REPORTSEC EDGAR · filed Mar 18, 2026 · fetched Nov 12, 2026
- S-1/A · REGISTRATION STATEMENTSEC EDGAR · filed Jan 22, 2026 · fetched Nov 12, 2026
- S-1/A · REGISTRATION STATEMENTSEC EDGAR · filed Jan 16, 2026 · fetched Nov 12, 2026
- 8-K · CURREN REPORTSEC EDGAR · filed Jan 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jan 6, 2026 · fetched Nov 12, 2026